KDL Biotech Ltd - Stock Valuation and Financial Performance

Name: KDL Biotech
Brand: KDL Biotech

BSE: 532291 | NSE: KOPDRUGS | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on KDL Biotech

Based on:

Data

M-Cap below 100cr DeciZen not available

KDL Biotech stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

5.1 Cr.

52-wk low:

2.1

52-wk high:

2.1

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of KDL Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'02	Mar'03	Mar'04	Sep'05	Mar'06	Sep'07	Sep'08	Mar'10	Mar'11	Mar'12	TTM
ROCE % ⓘ	6.1%	5.5%	1.8%	-24.1%	-6.8%	-4.8%	-14.2%	-21.4%	-105.3%	-129.4%	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	204	193	124	106	110	113	56.8	25.6	28.4	26.5	0
Sales YoY Gr.	-	-5.2%	-35.9%	-14.7%	4.4%	2.3%	-49.7%	-55%	11%	-6.8%	-
Adj EPS ⓘ	2.1	1.4	-1.8	-17.2	-13.5	-5.4	-8.5	-6	-23.4	-7.2	-5.9
YoY Gr.	-	-31.7%	-228.6%	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	35.5	36.1	35.2	6.9	0.3	-0.1	16.4	6.2	-17.5	-24.6	-42.5
Adj Net Profit ⓘ	3.4	2.4	-3	-28.9	-22.6	-9	-20.4	-14.5	-56.3	-17.2	-14
Cash Flow from Ops. ⓘ	-10.6	34.9	14.2	6.4	-1.9	1.7	-6.3	2.2	1.6	6.8	-
Debt/CF from Ops. ⓘ	-7.2	2	5	7.9	-84.3	32.2	-10.2	17.7	38.4	8.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-20.3%	-24.9%	-22.5%	-6.8%
Adj EPS ⓘ	-214.9%	NA	NA	NA
BVPSⓘ	-196%	-343.1%	-214.6%	NA
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'02	Mar'03	Mar'04	Sep'05	Mar'06	Sep'07	Sep'08	Mar'10	Mar'11	Mar'12	TTM
Return on Equity % ⓘ	4.1	2.6	-3.3	-64.7	-31.5	-104	-104.5	-70.2	573.9	34	17.6
Op. Profit Mgn % ⓘ	9.8	8.2	10.1	-11.7	-6.2	-6.4	-14.9	-26.4	-57.6	-7.8	NAN
Net Profit Mgn % ⓘ	1.7	1.2	-2.4	-27.3	-20.4	-8	-35.9	-56.5	-198.1	-65	-INF
Debt to Equity ⓘ	0.9	0.8	0.8	1.8	3	-308.8	1.6	2.6	-1.4	-1	-
Working Cap Days ⓘ	147	142	182	127	328	129	298	211	166	107	0
Cash Conv. Cycle ⓘ	62	63	58	39	90	22	-37	-60	-56	-18	0

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - KDL Biotech Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-5.9	-
TTM Sales (₹ Cr.)	0	-
BVPS (₹.) ⓘ	-42.5	-
Reserves (₹ Cr.) ⓘ	-126	-
P/BV ⓘ	-0.05	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	2.14 / 2.14
All Time Low / High (₹)	1.61 / 413.35
Market Cap (₹ Cr.)	5.1
Equity (₹ Cr.)	24
Face Value (₹)	10
Industry PE ⓘ	47.6

Management X-Ray of KDL Biotech:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of KDL Biotech

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of KDL Biotech

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'02	Mar'03	Mar'04	Sep'05	Mar'06	Sep'07	Sep'08	Mar'10	Mar'11	Mar'12
Sales	203.98	193.48	124.03	158.70	55.24	169.54	56.84	38.38	28.41	26.47
Operating Expenses ⓘ	184.03	177.53	111.50	177.19	58.65	180.34	66.32	48.50	44.76	28.53
Manufacturing Costs	6.33	6.12	6.89	10.51	7.44	13.74	11.71	12.59	11.82	12.07
Material Costs	164.38	156.59	90.63	127.62	44.22	150.08	33.92	16.83	7.64	4.63
Employee Cost	6.26	6.12	6.58	10.60	3.57	11.32	7.79	14.07	9.36	9.65
Other Costs ⓘ	7.07	8.71	7.39	28.47	3.42	5.19	12.90	5.01	15.95	2.18
Operating Profit ⓘ	19.94	15.94	12.53	-18.49	-3.41	-10.80	-9.47	-10.12	-16.36	-2.07
Operating Profit Margin (%)	9.8%	8.2%	10.1%	-11.7%	-6.2%	-6.4%	-16.7%	-26.4%	-57.6%	-7.8%
Other Income ⓘ	0.55	0.32	0.34	1.42	0.94	20.46	5.63	1.86	0.32	0.76
Interest ⓘ	8.49	9.39	8.49	13.38	5.14	12.94	10.35	2.99	6.74	6.77
Depreciation ⓘ	6.08	6.53	8.48	12.83	3.63	10.20	6.90	12.40	22.35	9.13
Exceptional Items ⓘ	0	0	0	0	0	0	0	6.66	-11.50	0
Profit Before Tax ⓘ	5.92	0.34	-4.10	-43.28	-11.25	-13.48	-21.09	-16.99	-56.62	-17.21
Tax ⓘ	2.18	-2.02	-1.10	0.02	0.03	0.06	0.04	0.02	7.69	0
Profit After Tax	3.75	2.36	-3	-43.30	-11.28	-13.55	-21.13	-17.01	-64.31	-17.21
PAT Margin (%)	1.8%	1.2%	-2.4%	-27.3%	-20.4%	-8.0%	-37.2%	-44.3%	-226.0%	-65.0%
Adjusted EPS (₹)	2.2	1.4	-1.8	-25.8	-6.7	-8.1	-8.8	-7.1	-26.8	-7.2
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'02	Mar'03	Mar'04	Sep'05	Mar'06	Sep'07	Sep'08	Mar'10	Mar'11	Mar'12
Equity and Liabilities
Shareholders Fund	89.22	91.58	88.58	45.29	26.31	-0.27	39.36	22.35	-41.96	-59.17
Share Capital ⓘ	42.83	42.83	42.83	42.83	42.83	16.76	24.04	24.04	24.04	24.04
Reserves ⓘ	46.39	48.75	45.75	2.46	-16.52	-17.03	15.33	-1.68	-66	-83.21
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	75.95	68.87	71.13	76.06	79.97	82.86	64.25	57.37	51.30	51.42
Long Term Debt	75.95	68.87	71.13	76.06	79.97	82.86	64.25	57.37	0.01	0.04
Short Term Debt	0	0	0	0	0	0	0	0	51.29	51.38
Trade Payables	30.42	31.78	26.16	26.58	28.38	52.92	10.87	21.78	5.33	5.48
Others Liabilities ⓘ	-0.33	0.99	-3.66	-1.05	4.91	10.45	-2.92	-3.19	50.68	58.97
Total Liabilities ⓘ	195.25	193.22	182.22	146.88	139.57	145.96	111.57	98.31	65.35	56.70
Fixed Assets
Gross Block	124.80	149.56	150.59	151.41	138.73	140.35	144.48	154.79	154.97	155.16
Accumulated Depreciation	24.23	30.73	39.21	51.88	52.13	62.30	67.63	80.03	91.36	100.45
Net Fixed Assetsⓘ	100.57	118.83	111.37	99.53	86.60	78.05	76.85	74.76	63.61	54.71
CWIP ⓘ	0	0	0	0	0	0	5.98	4.40	0	0
Investmentsⓘ	0.01	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.01	0.01
Inventories	43.05	20.96	17.11	17.24	14.29	29.67	5.20	3.47	2.70	2.51
Trade Receivables	31.99	32.83	30.92	23.93	31.86	22.58	1.04	0.07	0.29	0.02
Cash Equivalents	1.68	2.15	2.55	2.90	0.88	0.30	1.34	0.72	0.48	0.54
Others Assetsⓘ	17.95	18.44	20.26	3.25	5.93	15.35	21.14	14.89	-1.74	-1.08
Total Assets ⓘ	195.25	193.22	182.22	146.88	139.57	145.96	111.57	98.31	65.35	56.70

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'02	Mar'03	Mar'04	Sep'05	Mar'06	Sep'07	Sep'08	Mar'10	Mar'11	Mar'12
Cash Flow From Operating Activity ⓘ	-10.60	34.90	14.19	9.60	-0.95	2.57	-6.31	3.25	1.57	6.79
PBT ⓘ	5.92	0.34	-4.10	-43.28	-11.25	-13.48	-21.09	-16.99	-64.31	-17.21
Adjustment ⓘ	15.66	17.50	18.93	46.03	13.52	1.41	24.89	10.40	62.10	15.65
Changes in Working Capital ⓘ	-23.68	26.64	-0.62	6.89	-2.79	14.72	-10.07	9.85	4.21	8.78
Tax Paid ⓘ	-0.01	-0.19	-0.02	-0.05	-0.43	-0.08	-0.04	-0.02	-0.43	-0.43
Cash Flow From Investing Activity ⓘ	-2.92	-27.35	-0.93	-0.79	-0.29	-1.55	-15.03	-0.66	-0.08	0
Capex	-1.13	-24.76	-1.03	-1	-0.35	-1.59	-15.09	-0.82	-0.15	-0.24
Net Investments	-0.01	0	0	0	0	0	0	0	0	0
Others ⓘ	-1.78	-2.59	0.10	0.21	0.06	0.04	0.06	0.16	0.06	0.24
Cash Flow From Financing Activityⓘ	14.47	-7.08	-12.86	-8.45	-0.78	-1.60	22.38	-3.21	-1.79	-6.73
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	8.73	0	0	0
Net Proceeds from Borrowing ⓘ	14.47	-7.08	0	0	1.52	-41.13	0	0	0	0.03
Interest Paid ⓘ	0	0	-4.60	-7.06	0	-4.50	-10.27	-2.99	-1.84	-6.77
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	-8.26	-1.40	-2.30	44.03	23.92	-0.22	0.05	0
Net Cash Flow ⓘ	0.94	0.47	0.40	0.36	-2.02	-0.58	1.03	-0.62	-0.30	0.06

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'02	Mar'03	Mar'04	Sep'05	Mar'06	Sep'07	Sep'08	Mar'10	Mar'11	Mar'12
Ratios
ROE (%)	6.83	3.94	-5.02	-113.41	-127.67	N/A	-108.11	-55.12	N/A	N/A
ROCE (%)	9.65	6.14	2.81	-21.69	-5.41	N/A	-11.54	-15.27	N/A	N/A
Asset Turnover Ratio	1.1	1.04	0.7	1.02	0.42	1.26	0.47	0.38	0.35	0.45
PAT to CFO Conversion(x)	-2.83	14.79	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	56	59	88	59	169	55	72	5	2	2
Inventory Days	74	58	53	37	96	45	106	40	39	35
Payable Days	77	59	104	74	227	99	343	354	648	426

KDL Biotech Ltd Stock News

KDL Biotech Ltd FAQs

What is the share price of KDL Biotech?

Company share prices are keep on changing according to the market conditions. The closing price of KDL Biotech on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of KDL Biotech?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of KDL Biotech stood at ₹5.14.

What is the P/E ratio of KDL Biotech?

The latest P/E ratio of KDL Biotech as of 01-Jan-1970 05:30 is 0.00.

What is the P/B ratio of KDL Biotech?

The latest P/B ratio of KDL Biotech as of 01-Jan-1970 05:30 is -0.05.

What is the 52-week high and low of KDL Biotech?

The 52-week high of KDL Biotech is ₹2.14 and the 52-week low is ₹2.14.

What is the TTM revenue of KDL Biotech?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of KDL Biotech is ₹0.00 ( Cr.) .

About KDL Biotech Ltd

KDL Biotech, formerly known as Kopran Drugs was incorporated on August 12, 1986 as a private limited company. The bulk drugs division of Kopran at Khopoli was demerged and merged into KDL Biotech with effect from January 1, 1998 pursuant to order u/s 391 to 394 of the Companies Act by the Bombay High Court. The company is a joint venture between Kopran of Parijat Enterprises, India and Synpac Kingdom Pharmaceuticals of Koo Group, Taiwan.

KDL has a biotechnology division, which manufactures Penicillin-G acylase, the enzyme used for conversion of penicillin to 6APA. It has also successfully developed Bleomycin, an anti-cancer drug and a cytoxic antibiotic. The products under development include mitomycin, another anti-cancer drug and Vancomycin, an anti- bacterial.

KDL is one of the largest manufacturers of semi synthetic penicillin in Asia. From a 12 tonne per annum capacity in 1982-83, it expanded to a present capacity of 1200 tonnes per annum. The company's plant is approved by UK MCA, US FDA, South African MCC and several countries with strict compliance of GMP and GLP.

Milestones:

2000 - The union had declared a strike at the company's factory situated at Village Savroli, Taluka Khalapur, Khopoli, District Raigad, Maharashtra. The company's major foray into the business of biotechnology based products it was proposed to change the name of the company from Kopran Drugs to KDL Biotech for which necessary approval was been received from Registrar of Companies, Maharashtra, Mumbai. The company is a major producer of semi-synthetic penicillins (SSP) and the enzyme for converting penicillin-G to 6APA.

2001- Crisil downgraded the company's NCDs issue to `BB+' from `BBB'.

Products:

1. Finished Dosage Forms

â€¢ Antibiotics/Antibacterial sâ€¢ Anti-Malarial â€¢ Cadiovasculars â€¢ Pain Management â€¢ Anthelminthics

2. Active Pharmaceutical Ingredients

â€¢ Anti-hypertensives â€¢ Macrolides â€¢ Taste Masked â€¢ Cephalosporins

Subsidiary:

â€¢ Kopran Research Laboratories

Group companies:

â€¢ Oriental Containers â€¢ United Shippers â€¢ Shinrai Toyota â€¢ Claridge Moulded Fibre â€¢ Kopran

Alliances:

â€¢ Gujarat Themis Biosyn â€¢ Kampala Pharmaceutical Industries, Uganda